Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 55% Improvement Relative Risk Ventilation 69% Hospitalization 77% c19early.com/aa Patel et al. Antiandrogens for COVID-19 Prophylaxis Favors antiandrogen Favors control
Patel, 58 patient various antiandrogen prophylaxis study: 55% lower mortality [p=0.22], 69% lower ventilation [p=0.19], and 77% lower hospitalization [p=0.02] https://c19p.org/patel3
copied to clipboard
Does androgen deprivation therapy protect against severe complications from COVID-19?
Patel et al., Annals of Oncology, doi:10.1016/j.annonc.2020.06.023
9 Jul 2020    Source   PDF   Share   Tweet
Retrospective 58 prostate cancer patients in the USA, showing lower risk of hospitalization with ADT.
risk of death, 55.2% lower, RR 0.45, p = 0.22, treatment 4 of 22 (18.2%), control 10 of 36 (27.8%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of mechanical ventilation, 69.0% lower, OR 0.31, p = 0.19, treatment 22, control 36, adjusted per study, multivariable, RR approximated with OR.
risk of hospitalization, 77.0% lower, OR 0.23, p = 0.02, treatment 22, control 36, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Patel et al., 7/9/2020, retrospective, USA, North America, peer-reviewed, 7 authors, study period 1 March, 2020 - 4 June, 2020.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit